HCPCS Service Codes - Medical care

HCPCS Codes for Medical care

• J9349

  Injection, tafasitamab-cxix, 2 mg

• J9350

  Injection, mosunetuzumab-axgb, 1 mg

• J9351

  Injection, topotecan, 0.1 mg

• J9352

  Injection, trabectedin, 0.1 mg

• J9353

  Injection, margetuximab-cmkb, 5 mg

• J9354

  Injection, ado-trastuzumab emtansine, 1 mg

• J9355

  Injection, trastuzumab, excludes biosimilar, 10 mg

• J9356

  Injection, trastuzumab, 10 mg and hyaluronidase-oysk

• J9357

  Injection, valrubicin, intravesical, 200 mg

• J9358

  Injection, fam-trastuzumab deruxtecan-nxki, 1 mg

• J9359

  Injection, loncastuximab tesirine-lpyl, 0.075 mg

• J9360

  Injection, vinblastine sulfate, 1 mg

• J9361

  Injection, efbemalenograstim alfa-vuxw, 0.5 mg

• J9370

  Vincristine sulfate, 1 mg

• J9371

  Injection, vincristine sulfate liposome, 1 mg

• J9376

  Injection, pozelimab-bbfg, 1 mg

• J9380

  Injection, teclistamab-cqyv, 0.5 mg

• J9381

  Injection, teplizumab-mzwv, 5 mcg

• J9382

  Injection, zenocutuzumab-zbco, 1 mg

• J9390

  Injection, vinorelbine tartrate, 10 mg

• J9393

  Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg

• J9394

  Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg

• J9395

  Injection, fulvestrant, 25 mg

• J9400

  Injection, ziv-aflibercept, 1 mg

• J9600

  Injection, porfimer sodium, 75 mg

• J9601

  Injection, linvoseltamab-gcpt, 1 mg

• J9999

  Not otherwise classified, antineoplastic drugs

• M0001

  Advancing cancer care mips value pathways

• M0002

  Optimal care for kidney health mips value pathways

• M0003

  Optimal care for patients with episodic neurological conditions mips value pathways

• M0004

  Quality care for patients with neurological conditions mips value pathway

• M0005

  Value in primary care mips value pathway

• M0010

  Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services

• M0064

  Brief office visit for the sole purpose of monitoring or changing drug prescriptions used in the treatment of mental psychoneurotic and personality disorders

• M0075

  Cellular therapy

• M0076

  Prolotherapy

• M0100

  Intragastric hypothermia using gastric freezing

• M0300

  Iv chelation therapy (chemical endarterectomy)

• M1000

  Pain screened as moderate to severe

• M1001

  Plan of care to address moderate to severe pain documented on or before the date of the second visit with a clinician

• M1002

  Plan of care for moderate to severe pain not documented on or before the date of the second visit with a clinician, reason not given

• M1003

  Tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic and/or immune response modifier therapy

• M1004

  Documentation of medical reason for not screening for tb or interpreting results (i.e., patient positive for tb and documentation of past treatment; patient who has recently completed a course of anti-tb therapy)

• M1005

  Tb screening not performed or results not interpreted, reason not given

• M1006

  Disease activity not assessed, reason not given

• M1007

  >=50% of total number of a patient's outpatient ra encounters assessed

• M1008

  <50% of total number of a patient's outpatient ra encounters assessed

• M1009

  Discharge/discontinuation of the episode of care documented in the medical record

• M1010

  Discharge/discontinuation of the episode of care documented in the medical record

• M1011

  Discharge/discontinuation of the episode of care documented in the medical record